- Issuer ticker
-
AVLN
- Reported as of
-
29 Apr 2026
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
4 source fields
- SEC form
-
4
- Accepted by SEC
-
01 May 2026, 18:32:47 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Douglas Carlson
Key filing fact
Jon Congleton filed Form 4 for Avalyn Pharma Inc. (AVLN) on 01 May 2026.
Key facts
- This page summarizes Jon Congleton's Form 4 filing for Avalyn Pharma Inc. (AVLN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 May 2026, 18:32.
Change
- Previous filing in this sequence was filed on 15 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001644975
Primary reporting owner
Congleton Jon
- Relationship
-
Director
- Address
- C/O AVALYN PHARMA INC., 105 W FIRST STREET, BOSTON
- Signature
- /s/ Douglas Carlson
- Signature date
- 01 May 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVLN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +26,978
- Change %
- Price
-
$0.000000*
- Shares after
- 26,978
- Date
- 29 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,978
- Exercise price
- $18.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote